Trial Outcomes & Findings for Carboplatin, Abraxane, Avastin as Neoadjuvant Therapy for Her2-Negative Breast Cancer (NCT NCT00723125)
NCT ID: NCT00723125
Last Updated: 2021-04-29
Results Overview
Recruitment status
COMPLETED
Study phase
PHASE2
Target enrollment
60 participants
Primary outcome timeframe
at surgery approximately 5 months after initial treatment
Results posted on
2021-04-29
Participant Flow
DDAC: (dose-dense doxorubicin and cyclophosphamide (DDAC)
Participant milestones
| Measure |
Cohort 1
Avastin 10 mg/kg IV over 90 minutes day -14 Abraxane 100 mg/m2 IV over 30 minutes weekly x 12 weeks with Carboplatin at AUC 6 over 30 min IV and Avastin 15 mg/kg IV over 30-90 minutes weeks 1,4,7, and 10 Avastin 10 mg/kg IV over 30-60 minutes cycles 1-3 (omit dose with cycle 4) Doxorubicin 60 mg/m2\* and Cyclophosphamide 600 mg/m2 IV q2weeks x 4 cycles Definitive surgery Avastin 10 mg/kg IV over 30-60 minutes q2weeks x 34 weeks
Cohort 1 and Cohort 2: Abraxane 100 mg/m2 IV over 30 minutes weekly x 12 weeks with Carboplatin at AUC 6 over 30 min IV and Avastin 15 mg/kg IV over 30-90 minutes weeks 1,4,7, and 10 (in Cohort 2, omit dose of Avastin on week 10)
|
Cohort 2
Abraxane 100 mg/m2 IV over 30 minutes days -14 and -7 Abraxane 100 mg/m2 IV over 30 minutes weekly x 12 weeks with Carboplatin at AUC 6 over 30 min IV and Avastin 15 mg/kg IV over 30-90 minutes weeks 1,4,7, and 10 (in Cohort 2, omit dose of Avastin on week 10) Definitive surgery Avastin 10 mg/kg IV over 30-60 minutes and Doxorubicin 60 mg/m2\* and Cyclophosphamide 600 mg/m2 IV q2weeks x 4 cycles followed by Avastin 10 mg/kg IV over 30-60 minutes q2weeks x 34 weeks OR Avastin 10 mg/kg IV over 30-60 minutes q2weeks x 42 weeks
Cohort 1 and Cohort 2: Abraxane 100 mg/m2 IV over 30 minutes weekly x 12 weeks with Carboplatin at AUC 6 over 30 min IV and Avastin 15 mg/kg IV over 30-90 minutes weeks 1,4,7, and 10 (in Cohort 2, omit dose of Avastin on week 10)
|
|---|---|---|
|
Overall Study
STARTED
|
33
|
27
|
|
Overall Study
COMPLETED
|
15
|
21
|
|
Overall Study
NOT COMPLETED
|
18
|
6
|
Reasons for withdrawal
| Measure |
Cohort 1
Avastin 10 mg/kg IV over 90 minutes day -14 Abraxane 100 mg/m2 IV over 30 minutes weekly x 12 weeks with Carboplatin at AUC 6 over 30 min IV and Avastin 15 mg/kg IV over 30-90 minutes weeks 1,4,7, and 10 Avastin 10 mg/kg IV over 30-60 minutes cycles 1-3 (omit dose with cycle 4) Doxorubicin 60 mg/m2\* and Cyclophosphamide 600 mg/m2 IV q2weeks x 4 cycles Definitive surgery Avastin 10 mg/kg IV over 30-60 minutes q2weeks x 34 weeks
Cohort 1 and Cohort 2: Abraxane 100 mg/m2 IV over 30 minutes weekly x 12 weeks with Carboplatin at AUC 6 over 30 min IV and Avastin 15 mg/kg IV over 30-90 minutes weeks 1,4,7, and 10 (in Cohort 2, omit dose of Avastin on week 10)
|
Cohort 2
Abraxane 100 mg/m2 IV over 30 minutes days -14 and -7 Abraxane 100 mg/m2 IV over 30 minutes weekly x 12 weeks with Carboplatin at AUC 6 over 30 min IV and Avastin 15 mg/kg IV over 30-90 minutes weeks 1,4,7, and 10 (in Cohort 2, omit dose of Avastin on week 10) Definitive surgery Avastin 10 mg/kg IV over 30-60 minutes and Doxorubicin 60 mg/m2\* and Cyclophosphamide 600 mg/m2 IV q2weeks x 4 cycles followed by Avastin 10 mg/kg IV over 30-60 minutes q2weeks x 34 weeks OR Avastin 10 mg/kg IV over 30-60 minutes q2weeks x 42 weeks
Cohort 1 and Cohort 2: Abraxane 100 mg/m2 IV over 30 minutes weekly x 12 weeks with Carboplatin at AUC 6 over 30 min IV and Avastin 15 mg/kg IV over 30-90 minutes weeks 1,4,7, and 10 (in Cohort 2, omit dose of Avastin on week 10)
|
|---|---|---|
|
Overall Study
Met Dx
|
1
|
0
|
|
Overall Study
Withdrawal by Subject
|
15
|
6
|
|
Overall Study
Adverse Event
|
2
|
0
|
Baseline Characteristics
Carboplatin, Abraxane, Avastin as Neoadjuvant Therapy for Her2-Negative Breast Cancer
Baseline characteristics by cohort
| Measure |
Cohort 1
n=33 Participants
Avastin 10 mg/kg IV over 90 minutes day -14 Abraxane 100 mg/m2 IV over 30 minutes weekly x 12 weeks with Carboplatin at AUC 6 over 30 min IV and Avastin 15 mg/kg IV over 30-90 minutes weeks 1,4,7, and 10 Avastin 10 mg/kg IV over 30-60 minutes cycles 1-3 (omit dose with cycle 4) Doxorubicin 60 mg/m2\* and Cyclophosphamide 600 mg/m2 IV q2weeks x 4 cycles Definitive surgery Avastin 10 mg/kg IV over 30-60 minutes q2weeks x 34 weeks
Cohort 1 and Cohort 2: Abraxane 100 mg/m2 IV over 30 minutes weekly x 12 weeks with Carboplatin at AUC 6 over 30 min IV and Avastin 15 mg/kg IV over 30-90 minutes weeks 1,4,7, and 10 (in Cohort 2, omit dose of Avastin on week 10)
|
Cohort 2
n=27 Participants
Abraxane 100 mg/m2 IV over 30 minutes days -14 and -7 Abraxane 100 mg/m2 IV over 30 minutes weekly x 12 weeks with Carboplatin at AUC 6 over 30 min IV and Avastin 15 mg/kg IV over 30-90 minutes weeks 1,4,7, and 10 (in Cohort 2, omit dose of Avastin on week 10) Definitive surgery Avastin 10 mg/kg IV over 30-60 minutes and Doxorubicin 60 mg/m2\* and Cyclophosphamide 600 mg/m2 IV q2weeks x 4 cycles followed by Avastin 10 mg/kg IV over 30-60 minutes q2weeks x 34 weeks OR Avastin 10 mg/kg IV over 30-60 minutes q2weeks x 42 weeks
Cohort 1 and Cohort 2: Abraxane 100 mg/m2 IV over 30 minutes weekly x 12 weeks with Carboplatin at AUC 6 over 30 min IV and Avastin 15 mg/kg IV over 30-90 minutes weeks 1,4,7, and 10 (in Cohort 2, omit dose of Avastin on week 10)
|
Total
n=60 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Continuous
|
47.6 years
n=5 Participants
|
45.8 years
n=7 Participants
|
46.8 years
n=5 Participants
|
|
Age, Categorical
<=18 years
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
|
Age, Categorical
Between 18 and 65 years
|
32 Participants
n=5 Participants
|
27 Participants
n=7 Participants
|
59 Participants
n=5 Participants
|
|
Age, Categorical
>=65 years
|
1 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
1 Participants
n=5 Participants
|
|
Sex/Gender, Customized
Female
|
33 participants
n=5 Participants
|
27 participants
n=7 Participants
|
60 participants
n=5 Participants
|
|
Region of Enrollment
United States
|
33 participants
n=5 Participants
|
27 participants
n=7 Participants
|
60 participants
n=5 Participants
|
PRIMARY outcome
Timeframe: at surgery approximately 5 months after initial treatmentOutcome measures
| Measure |
Cohort 1
n=28 Participants
Avastin 10 mg/kg IV over 90 minutes day -14 Abraxane 100 mg/m2 IV over 30 minutes weekly x 12 weeks with Carboplatin at AUC 6 over 30 min IV and Avastin 15 mg/kg IV over 30-90 minutes weeks 1,4,7, and 10 Avastin 10 mg/kg IV over 30-60 minutes cycles 1-3 (omit dose with cycle 4) Doxorubicin 60 mg/m2\* and Cyclophosphamide 600 mg/m2 IV q2weeks x 4 cycles Definitive surgery Avastin 10 mg/kg IV over 30-60 minutes q2weeks x 34 weeks
Cohort 1 and Cohort 2: Abraxane 100 mg/m2 IV over 30 minutes weekly x 12 weeks with Carboplatin at AUC 6 over 30 min IV and Avastin 15 mg/kg IV over 30-90 minutes weeks 1,4,7, and 10 (in Cohort 2, omit dose of Avastin on week 10)
|
Cohort 2
n=27 Participants
Abraxane 100 mg/m2 IV over 30 minutes days -14 and -7 Abraxane 100 mg/m2 IV over 30 minutes weekly x 12 weeks with Carboplatin at AUC 6 over 30 min IV and Avastin 15 mg/kg IV over 30-90 minutes weeks 1,4,7, and 10 (in Cohort 2, omit dose of Avastin on week 10) Definitive surgery Avastin 10 mg/kg IV over 30-60 minutes and Doxorubicin 60 mg/m2\* and Cyclophosphamide 600 mg/m2 IV q2weeks x 4 cycles followed by Avastin 10 mg/kg IV over 30-60 minutes q2weeks x 34 weeks OR Avastin 10 mg/kg IV over 30-60 minutes q2weeks x 42 weeks
Cohort 1 and Cohort 2: Abraxane 100 mg/m2 IV over 30 minutes weekly x 12 weeks with Carboplatin at AUC 6 over 30 min IV and Avastin 15 mg/kg IV over 30-90 minutes weeks 1,4,7, and 10 (in Cohort 2, omit dose of Avastin on week 10)
|
|---|---|---|
|
Pathological Complete Response Rates at Surgery
|
16 participants
|
2 participants
|
SECONDARY outcome
Timeframe: 2 yearsPopulation: Pts with clinical stage IIA-IIIC BrCa
Measure of safety and tolerability according to CTCAE version 3.0
Outcome measures
| Measure |
Cohort 1
n=28 Participants
Avastin 10 mg/kg IV over 90 minutes day -14 Abraxane 100 mg/m2 IV over 30 minutes weekly x 12 weeks with Carboplatin at AUC 6 over 30 min IV and Avastin 15 mg/kg IV over 30-90 minutes weeks 1,4,7, and 10 Avastin 10 mg/kg IV over 30-60 minutes cycles 1-3 (omit dose with cycle 4) Doxorubicin 60 mg/m2\* and Cyclophosphamide 600 mg/m2 IV q2weeks x 4 cycles Definitive surgery Avastin 10 mg/kg IV over 30-60 minutes q2weeks x 34 weeks
Cohort 1 and Cohort 2: Abraxane 100 mg/m2 IV over 30 minutes weekly x 12 weeks with Carboplatin at AUC 6 over 30 min IV and Avastin 15 mg/kg IV over 30-90 minutes weeks 1,4,7, and 10 (in Cohort 2, omit dose of Avastin on week 10)
|
Cohort 2
n=27 Participants
Abraxane 100 mg/m2 IV over 30 minutes days -14 and -7 Abraxane 100 mg/m2 IV over 30 minutes weekly x 12 weeks with Carboplatin at AUC 6 over 30 min IV and Avastin 15 mg/kg IV over 30-90 minutes weeks 1,4,7, and 10 (in Cohort 2, omit dose of Avastin on week 10) Definitive surgery Avastin 10 mg/kg IV over 30-60 minutes and Doxorubicin 60 mg/m2\* and Cyclophosphamide 600 mg/m2 IV q2weeks x 4 cycles followed by Avastin 10 mg/kg IV over 30-60 minutes q2weeks x 34 weeks OR Avastin 10 mg/kg IV over 30-60 minutes q2weeks x 42 weeks
Cohort 1 and Cohort 2: Abraxane 100 mg/m2 IV over 30 minutes weekly x 12 weeks with Carboplatin at AUC 6 over 30 min IV and Avastin 15 mg/kg IV over 30-90 minutes weeks 1,4,7, and 10 (in Cohort 2, omit dose of Avastin on week 10)
|
|---|---|---|
|
Number of Participants With Adverse Events
|
15 participants
|
21 participants
|
Adverse Events
Cohort 1 Neo-adjuvant
Serious events: 5 serious events
Other events: 28 other events
Deaths: 0 deaths
Cohort 2 Neo-adjuvant
Serious events: 8 serious events
Other events: 27 other events
Deaths: 0 deaths
Cohort 1 DDAC
Serious events: 10 serious events
Other events: 27 other events
Deaths: 0 deaths
Cohort 2 DDAC
Serious events: 7 serious events
Other events: 16 other events
Deaths: 0 deaths
Cohort 1 Adjuvant Post Surgery
Serious events: 2 serious events
Other events: 5 other events
Deaths: 0 deaths
Cohort 2 Adjuvant Post Surgery
Serious events: 7 serious events
Other events: 18 other events
Deaths: 0 deaths
Serious adverse events
| Measure |
Cohort 1 Neo-adjuvant
n=28 participants at risk
Avastin 10 mg/kg IV over 90 minutes day -14 Abraxane 100 mg/m2 IV over 30 minutes weekly x 12 weeks with Carboplatin at AUC 6 over 30 min IV and Avastin 15 mg/kg IV over 30-90 minutes weeks 1,4,7, and 10
|
Cohort 2 Neo-adjuvant
n=27 participants at risk
Abraxane 100 mg/m2 IV over 30 minutes days -14 and -7 Abraxane 100 mg/m2 IV over 30 minutes weekly x 12 weeks with Carboplatin at AUC 6 over 30 min IV and Avastin 15 mg/kg IV over 30-90 minutes weeks 1,4,7, and 10 (in Cohort 2, omit dose of Avastin on week 10)
|
Cohort 1 DDAC
n=27 participants at risk
Avastin 10 mg/kg IV over 30-60 minutes cycles 1-3 (omit dose with cycle 4) Doxorubicin 60 mg/m2\* and Cyclophosphamide 600 mg/m2 IV q2weeks x 4 cycles
|
Cohort 2 DDAC
n=24 participants at risk
Avastin 10 mg/kg IV over 30-60 minutes and Doxorubicin 60 mg/m2\* and Cyclophosphamide 600 mg/m2 IV q2weeks x 4 cycles
|
Cohort 1 Adjuvant Post Surgery
n=15 participants at risk
Avastin 10 mg/kg IV over 30-60 minutes q2weeks x 34 weeks
|
Cohort 2 Adjuvant Post Surgery
n=21 participants at risk
Avastin 10 mg/kg IV over 30-60 minutes q2weeks x 34 weeks OR Avastin 10 mg/kg IV over 30-60 minutes q2weeks x 42 weeks
|
|---|---|---|---|---|---|---|
|
Investigations
gr 3 Nausea, gr 3 vomiting
|
3.6%
1/28 • Number of events 1 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/27 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/27 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/24 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/15 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/21 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
|
Investigations
gr 3 nausea, gr 2 infection with noraml ANC, gr 2 HGB, gr 1 glucose
|
3.6%
1/28 • Number of events 1 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/27 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/27 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/24 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/15 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/21 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
|
Investigations
gr 2 non-cardiac chest pain, gr 2 anemia
|
3.6%
1/28 • Number of events 1 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/27 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/27 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/24 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/15 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/21 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
|
Investigations
FN-gr 1 fever, gr 3 ANC (gr 3 infection)
|
0.00%
0/28 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
3.7%
1/27 • Number of events 1 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/27 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/24 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/15 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/21 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
|
Investigations
anemia 2
|
0.00%
0/28 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/27 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
3.7%
1/27 • Number of events 1 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/24 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/15 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/21 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
|
Investigations
Post surgery: gr 3 infection
|
0.00%
0/28 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/27 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/27 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/24 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
6.7%
1/15 • Number of events 1 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/21 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
|
Investigations
weakness gr 4
|
0.00%
0/28 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/27 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
3.7%
1/27 • Number of events 1 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/24 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/15 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/21 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
|
Investigations
FN gr 3, ANC 3, anemia gr 2, thrombocytopenia gr 3
|
0.00%
0/28 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/27 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
3.7%
1/27 • Number of events 1 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/24 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/15 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/21 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
|
Investigations
FN gr 4 (fever gr 1, ANC 4), cough 2, nasal congestion 2
|
0.00%
0/28 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/27 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/27 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
4.2%
1/24 • Number of events 1 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/15 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/21 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
|
Investigations
FN (fever gr 1, ANC 4) Anemia 2
|
0.00%
0/28 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/27 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/27 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
4.2%
1/24 • Number of events 1 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/15 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/21 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
|
Investigations
bleeding from JP drain grade 1
|
0.00%
0/28 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/27 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/27 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
4.2%
1/24 • Number of events 1 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/15 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/21 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
|
Investigations
FN- fever gr 1, ANC 4
|
0.00%
0/28 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/27 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/27 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
4.2%
1/24 • Number of events 1 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/15 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/21 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
|
Investigations
FN gr 3 (fever gr 1, ANC gr 3)
|
0.00%
0/28 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/27 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/27 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
4.2%
1/24 • Number of events 1 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/15 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/21 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
|
Investigations
gr 4 skin breakdown
|
0.00%
0/28 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/27 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/27 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/24 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
6.7%
1/15 • Number of events 1 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/21 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
|
Investigations
gr 2 pleural effusion
|
0.00%
0/28 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/27 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/27 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/24 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
6.7%
1/15 • Number of events 1 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/21 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
|
Investigations
grade 1 fever, gr 3 malignant pleural effusion
|
0.00%
0/28 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/27 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/27 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/24 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
6.7%
1/15 • Number of events 1 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/21 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
|
Investigations
breast cellulitis gr 3, acute renal injury gr 2, diarrhea gr 1, hemmorrhage GI gr 3
|
0.00%
0/28 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/27 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/27 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/24 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/15 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
4.8%
1/21 • Number of events 1 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
|
Investigations
post radiation- gr 3 wound complication would dehiscence
|
0.00%
0/28 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/27 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/27 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/24 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/15 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
4.8%
1/21 • Number of events 1 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
|
Investigations
gr 2 right arm weakness- motor neuropthay, right shoulder pain- r/o TIA
|
0.00%
0/28 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/27 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/27 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/24 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/15 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
4.8%
1/21 • Number of events 1 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
|
Investigations
Left breast pain gr 2
|
0.00%
0/28 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/27 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/27 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/24 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/15 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
4.8%
1/21 • Number of events 1 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
|
Investigations
PE gr 4, fever gr 2
|
0.00%
0/28 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/27 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/27 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/24 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/15 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
4.8%
1/21 • Number of events 1 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
|
Investigations
post op comp breast cellulitis gr3, migraine gr2
|
0.00%
0/28 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/27 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/27 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/24 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/15 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
4.8%
1/21 • Number of events 1 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
|
Investigations
related to reconstruction: infection with normal ANC- post complication healing issue (3)
|
0.00%
0/28 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/27 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/27 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/24 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/15 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
4.8%
1/21 • Number of events 1 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
|
Investigations
gr 3 infection (normal ANC) (cellulitis & pain in buttock - RT infection), gr 1 epistaxis
|
3.6%
1/28 • Number of events 1 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/27 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/27 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/24 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/15 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/21 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
|
Investigations
K gr 4,mental status gr 4, ventricular arrythmia gr 4, pneumonia gr 3
|
3.6%
1/28 • Number of events 1 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/27 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/27 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/24 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/15 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/21 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
|
Investigations
Acute Kidney Injury gr 2
|
0.00%
0/28 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
3.7%
1/27 • Number of events 1 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/27 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/24 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/15 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/21 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
|
Investigations
gr 4 GI Bleed (lesion in colon- villious adenoma)
|
0.00%
0/28 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
3.7%
1/27 • Number of events 1 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/27 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/24 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/15 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/21 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
|
Investigations
gr 2 Pleural effusion
|
3.6%
1/28 • Number of events 1 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/27 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/27 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/24 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/15 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/21 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
|
Investigations
cr 2, dehydration2, anemia2, weight loss2, fatigue-1, dysgeusia-2, gastritis-2, anorexia-2
|
3.6%
1/28 • Number of events 1 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/27 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/27 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/24 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/15 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/21 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
|
Investigations
Mucositis gr 3, fever gr 1, fatigue gr 1
|
0.00%
0/28 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
3.7%
1/27 • Number of events 1 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/27 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/24 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/15 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/21 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
|
Investigations
FN (fever gr1, ANC 3, infection3)- however during hospitalization ANC rose to grade 4
|
0.00%
0/28 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
3.7%
1/27 • Number of events 1 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/27 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
4.2%
1/24 • Number of events 1 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/15 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/21 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
|
Investigations
gr 4 ANC, gr 2 bleeding hemorrhoid, gr 2 rectal pain, dizziness gr 2
|
0.00%
0/28 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
3.7%
1/27 • Number of events 1 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/27 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/24 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/15 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/21 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
|
Investigations
left groin abcess- gr 2 1/14/14**amended to grade 3**
|
0.00%
0/28 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
3.7%
1/27 • Number of events 1 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/27 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/24 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/15 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/21 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
|
Investigations
dehydration gr 3, worsening anemia gr 3, diarrhea gr2, anorexia gr 2, ANC 3
|
0.00%
0/28 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
3.7%
1/27 • Number of events 1 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/27 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/24 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/15 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/21 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
|
Investigations
gr 3 FN (gr 3 infection, gr 3 ANC), gr 3 mucositis, gr 2 Diarrhea, Gr 2 pain rectal
|
0.00%
0/28 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/27 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
3.7%
1/27 • Number of events 1 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/24 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/15 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/21 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
|
Investigations
gr 3 periorbital cellulitis associated with chalazia, gr 2 anemia
|
0.00%
0/28 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/27 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
3.7%
1/27 • Number of events 1 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/24 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/15 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/21 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
|
Investigations
gr 4 ANC
|
0.00%
0/28 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/27 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
3.7%
1/27 • Number of events 1 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/24 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/15 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/21 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
|
Investigations
gr 2 dehydration, gr 2 wt loss, gr 2 anorexia, gr 3 esophagitis, gr 2 mucositis, gr 3 ANC, Gr 4 PLT
|
0.00%
0/28 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/27 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
3.7%
1/27 • Number of events 1 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/24 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/15 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/21 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
|
Investigations
gr3 FN, gr3 HGB, Gr2 fatigue, gr2 nausea, gr2 anorexia, gr2 dehydration, gr1 fever, gr1 epistaxis
|
0.00%
0/28 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/27 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
3.7%
1/27 • Number of events 1 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/24 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/15 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/21 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
|
Investigations
ANC 4, HGB 3, PLT 3
|
0.00%
0/28 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/27 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
3.7%
1/27 • Number of events 1 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/24 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/15 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/21 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
|
Investigations
FN gr3, bradycardia gr1, infection gr3, pancytopenia gr3, sore throat gr1, body aches gr1,rigors gr1
|
0.00%
0/28 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/27 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
3.7%
1/27 • Number of events 1 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/24 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/15 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/21 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
|
Investigations
dehydration2, k3, nausea2, anemia2, cpain2, SOB1, FN, vomiting2, PLT 4, mucositis2, fatigue2
|
0.00%
0/28 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/27 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
3.7%
1/27 • Number of events 1 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/24 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/15 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/21 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
|
Investigations
gr 2 odynophagia, gr 2 allergic rxn, gr 2 oral thrush, gr 4 ANC
|
0.00%
0/28 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/27 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/27 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
4.2%
1/24 • Number of events 1 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/15 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/21 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
|
Investigations
Post Op and Pre-drug- gr 1 fever,gr 2 erythema, gr 2 chills
|
0.00%
0/28 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/27 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/27 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
4.2%
1/24 • Number of events 1 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/15 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/21 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
|
Investigations
Post op- wound infection gr 2 on DIEP flap
|
0.00%
0/28 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/27 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/27 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
4.2%
1/24 • Number of events 1 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/15 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/21 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
|
Investigations
Post Reconstruction Surgery- infection left breast gr 3
|
0.00%
0/28 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/27 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/27 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/24 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/15 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
4.8%
1/21 • Number of events 1 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
|
Investigations
secondary malignancy: bladder cancer potentially related to DDAC
|
0.00%
0/28 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/27 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/27 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/24 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/15 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
4.8%
1/21 • Number of events 1 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
Other adverse events
| Measure |
Cohort 1 Neo-adjuvant
n=28 participants at risk
Avastin 10 mg/kg IV over 90 minutes day -14 Abraxane 100 mg/m2 IV over 30 minutes weekly x 12 weeks with Carboplatin at AUC 6 over 30 min IV and Avastin 15 mg/kg IV over 30-90 minutes weeks 1,4,7, and 10
|
Cohort 2 Neo-adjuvant
n=27 participants at risk
Abraxane 100 mg/m2 IV over 30 minutes days -14 and -7 Abraxane 100 mg/m2 IV over 30 minutes weekly x 12 weeks with Carboplatin at AUC 6 over 30 min IV and Avastin 15 mg/kg IV over 30-90 minutes weeks 1,4,7, and 10 (in Cohort 2, omit dose of Avastin on week 10)
|
Cohort 1 DDAC
n=27 participants at risk
Avastin 10 mg/kg IV over 30-60 minutes cycles 1-3 (omit dose with cycle 4) Doxorubicin 60 mg/m2\* and Cyclophosphamide 600 mg/m2 IV q2weeks x 4 cycles
|
Cohort 2 DDAC
n=24 participants at risk
Avastin 10 mg/kg IV over 30-60 minutes and Doxorubicin 60 mg/m2\* and Cyclophosphamide 600 mg/m2 IV q2weeks x 4 cycles
|
Cohort 1 Adjuvant Post Surgery
n=15 participants at risk
Avastin 10 mg/kg IV over 30-60 minutes q2weeks x 34 weeks
|
Cohort 2 Adjuvant Post Surgery
n=21 participants at risk
Avastin 10 mg/kg IV over 30-60 minutes q2weeks x 34 weeks OR Avastin 10 mg/kg IV over 30-60 minutes q2weeks x 42 weeks
|
|---|---|---|---|---|---|---|
|
Investigations
WBC
|
82.1%
23/28 • Number of events 23 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
100.0%
27/27 • Number of events 27 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
18.5%
5/27 • Number of events 5 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
33.3%
8/24 • Number of events 8 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/15 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
14.3%
3/21 • Number of events 3 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
|
Investigations
ANC
|
85.7%
24/28 • Number of events 24 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
81.5%
22/27 • Number of events 22 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
14.8%
4/27 • Number of events 4 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
16.7%
4/24 • Number of events 4 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/15 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
9.5%
2/21 • Number of events 2 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
|
Investigations
Neurosensory
|
10.7%
3/28 • Number of events 3 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
63.0%
17/27 • Number of events 17 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/27 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/24 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/15 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/21 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
|
Investigations
Neuromuscular
|
14.3%
4/28 • Number of events 4 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
22.2%
6/27 • Number of events 6 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
7.4%
2/27 • Number of events 2 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/24 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/15 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/21 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
|
Investigations
Hyponatremia
|
14.3%
4/28 • Number of events 4 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
18.5%
5/27 • Number of events 5 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
14.8%
4/27 • Number of events 4 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/24 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/15 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/21 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
|
Investigations
Hypokalemia
|
17.9%
5/28 • Number of events 5 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
25.9%
7/27 • Number of events 7 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
18.5%
5/27 • Number of events 5 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/24 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
6.7%
1/15 • Number of events 1 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/21 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
|
Investigations
Hypomagnesmia
|
42.9%
12/28 • Number of events 12 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
14.8%
4/27 • Number of events 4 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
37.0%
10/27 • Number of events 10 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/24 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/15 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
4.8%
1/21 • Number of events 1 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
|
Investigations
Hypocalcemia
|
17.9%
5/28 • Number of events 5 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
44.4%
12/27 • Number of events 12 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/27 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/24 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/15 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/21 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
|
Investigations
Alk-Phos abnormality
|
14.3%
4/28 • Number of events 4 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
18.5%
5/27 • Number of events 5 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
11.1%
3/27 • Number of events 3 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/24 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/15 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/21 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
|
Investigations
Cough
|
0.00%
0/28 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
25.9%
7/27 • Number of events 7 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/27 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/24 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/15 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/21 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
|
Investigations
epistaxis or bleeding
|
46.4%
13/28 • Number of events 13 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
88.9%
24/27 • Number of events 24 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
18.5%
5/27 • Number of events 5 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
50.0%
12/24 • Number of events 12 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
13.3%
2/15 • Number of events 2 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
33.3%
7/21 • Number of events 7 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
|
Investigations
Chest Pain/Bradycardia
|
0.00%
0/28 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
7.4%
2/27 • Number of events 2 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
7.4%
2/27 • Number of events 2 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
12.5%
3/24 • Number of events 3 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/15 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/21 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
|
Investigations
HTN
|
10.7%
3/28 • Number of events 3 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
11.1%
3/27 • Number of events 3 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
11.1%
3/27 • Number of events 3 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/24 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
13.3%
2/15 • Number of events 2 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
33.3%
7/21 • Number of events 7 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
|
Investigations
SOB
|
10.7%
3/28 • Number of events 3 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
11.1%
3/27 • Number of events 3 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/27 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/24 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/15 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/21 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
|
Investigations
Proteinuria
|
0.00%
0/28 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
11.1%
3/27 • Number of events 3 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/27 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/24 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/15 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
14.3%
3/21 • Number of events 3 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
|
Investigations
Ocular
|
0.00%
0/28 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
48.1%
13/27 • Number of events 13 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/27 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/24 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/15 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/21 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
|
Investigations
Hyperbili
|
0.00%
0/28 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/27 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/27 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/24 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/15 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
4.8%
1/21 • Number of events 1 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
|
Investigations
PLT
|
89.3%
25/28 • Number of events 25 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
74.1%
20/27 • Number of events 20 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
48.1%
13/27 • Number of events 13 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
8.3%
2/24 • Number of events 2 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/15 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/21 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
|
Investigations
HGB
|
96.4%
27/28 • Number of events 27 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
88.9%
24/27 • Number of events 24 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
77.8%
21/27 • Number of events 21 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/24 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/15 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/21 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
|
Investigations
Infection
|
17.9%
5/28 • Number of events 5 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
22.2%
6/27 • Number of events 6 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/27 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/24 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/15 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/21 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
|
Investigations
Myalgias
|
0.00%
0/28 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
40.7%
11/27 • Number of events 11 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
18.5%
5/27 • Number of events 5 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/24 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/15 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
9.5%
2/21 • Number of events 2 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
|
Investigations
Creatinine
|
0.00%
0/28 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
11.1%
3/27 • Number of events 3 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
7.4%
2/27 • Number of events 2 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/24 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/15 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/21 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
|
Investigations
Anorexia
|
14.3%
4/28 • Number of events 4 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
81.5%
22/27 • Number of events 22 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
18.5%
5/27 • Number of events 5 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/24 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/15 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
4.8%
1/21 • Number of events 1 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
|
Investigations
Wt loss
|
10.7%
3/28 • Number of events 3 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
18.5%
5/27 • Number of events 5 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
7.4%
2/27 • Number of events 2 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/24 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/15 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/21 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
|
Investigations
Fatigue
|
71.4%
20/28 • Number of events 20 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
96.3%
26/27 • Number of events 26 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
63.0%
17/27 • Number of events 17 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/24 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/15 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
19.0%
4/21 • Number of events 4 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
|
Investigations
Rash
|
7.1%
2/28 • Number of events 2 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/27 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/27 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/24 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/15 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/21 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
|
Investigations
Nausea
|
42.9%
12/28 • Number of events 12 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
81.5%
22/27 • Number of events 22 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
40.7%
11/27 • Number of events 11 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/24 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/15 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/21 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
|
Investigations
Vomiting
|
21.4%
6/28 • Number of events 6 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
33.3%
9/27 • Number of events 9 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
11.1%
3/27 • Number of events 3 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/24 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/15 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/21 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
|
Investigations
Mucositis
|
21.4%
6/28 • Number of events 6 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
59.3%
16/27 • Number of events 16 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/27 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/24 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/15 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
4.8%
1/21 • Number of events 1 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
|
Investigations
Rhinitis
|
17.9%
5/28 • Number of events 5 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
59.3%
16/27 • Number of events 16 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/27 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/24 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/15 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/21 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
|
Investigations
Diarrhea
|
32.1%
9/28 • Number of events 9 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
51.9%
14/27 • Number of events 14 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
7.4%
2/27 • Number of events 2 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/24 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/15 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/21 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
|
Investigations
LFTs
|
35.7%
10/28 • Number of events 10 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
44.4%
12/27 • Number of events 12 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
25.9%
7/27 • Number of events 7 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/24 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
0.00%
0/15 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
14.3%
3/21 • Number of events 3 • After run-in therapy neo-adjuvantly, throughout treatment and until completion of follow-up (5 years of follow-up) for a total of approximately 6.5 years
C1 neo: 33 patients enrolled to cohort 1 Neo-adjuvant, only 28 were evaluable C2 neo: 27 enrolled/evaluable cohort 2 Neo-adjuvant C1 DDAC: Of 28 patient evaluable neo-adjuvant, 27 treated DDAC C2 DDAC: Of 27 patients neo-adjuvant, 24 on DDAC C1 Avastin: Of 27 DDAC, 15 Avastin post-op C2 Avastin: Of 24 DDAC, 21 Avastin post-op
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place